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Abstract
Chronic infections resulting from biofilm formation are difficult to eradicate with current antimicrobial agents and
consequently new therapies are needed. This work demonstrates that the carbon monoxide-releasing molecule CORM-2,
previously shown to kill planktonic bacteria, also attenuates surface-associated growth of the Gram-negative pathogen
Pseudomonas aeruginosa by both preventing biofilm maturation and killing bacteria within the established biofilm. CORM-2
treatment has an additive effect when combined with tobramycin, a drug commonly used to treat P. aeruginosa lung
infections. CORM-2 inhibited biofilm formation and planktonic growth of the majority of clinical P. aeruginosa isolates
tested, for both mucoid and non-mucoid strains. While CORM-2 treatment increased the production of reactive oxygen
species by P. aeruginosa biofilms, this increase did not correlate with bacterial death. These data demonstrate that CO-RMs
possess potential novel therapeutic properties against a subset of P. aeruginosa biofilm related infections.
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Introduction
Organized bacterial communities or biofilms are formed on
both biotic and abiotic surfaces during infections by a wide variety
of Gram-positive and Gram-negative pathogens [1]. The bacteria
are protected from both the immune system and antimicrobials by
an extracellular matrix leading to prolonged colonization of the
host [2]. Therefore, new approaches to biofilm eradication and the
treatment of chronic biofilm-associated infections are needed. P.
aeruginosa is an opportunistic Gram-negative pathogen that has
served as a model organism to study the dynamics of biofilm
assembly and maintenance [3]. Since P. aeruginosa causes chronic
infection in patients with underlying lung disease such as cystic
fibrosis (CF), therapies that disrupt or prevent P. aeruginosa biofilm
formation are of critical clinical interest [4,5].
Carbon monoxide (CO) is a product of heme oxygenase activity
that serves as an anti-inflammatory signaling molecule in
mammalian cells [6,7] by binding, among others, divalent metals
of heme-containing proteins such as guanylate cyclase, mitochon-
drial cytocrome c oxidase and NADPH oxidase [8,9,10]. CO
selectively inhibits the expression of pro-inflammatory cytokines,
increasing the anti-inflammatory cytokine IL-10 [11,12,13] and
reducing neutrophil migration in septic lungs by suppressing
transendothelial migration [14]. CO inhalation has been reported
to exert an anti-inflammatory effect in patients with chronic
obstructive pulmonary disease [15]. Exogenous administration of
low concentrations of CO (10–500 ppm) by inhalation is currently
in a phase I clinical trial to evaluate its potential to reduce acute
airway inflammation (NCT00094406).
Due to concerns about delivering gaseous CO, which cannot be
precisely controlled and could be toxic to tissue with prolonged
exposure, chemical carriers of this gas known as CO-releasing
molecules (CO-RMs) have been developed [6,16]. These carbonyl
complexes contain a transition metal bound to CO that is released
once in solution. Recent studies in bacteria, including P. aeruginosa,
Staphylococcus aureus, and Escherichia coli, show that CO liberated
from CO-RMs binds primarily to the heme moieties of proteins in
the electron transport chain resulting in decreased oxygen
consumption and rapid cell death [17,18,19]. Exposure of E. coli
to CO-RMs also increases intracellular reactive oxygen species
(ROS) resulting in bacterial DNA damage and death [20]. Thus,
in addition to their anti-inflammatory properties, CO-RMs
potentially represent a novel class of antimicrobials. While the
water-soluble CORM-3 efficiently kills planktonic P. aeruginosa at
concentrations as low as 1 mM [18], the effect of CO-RMs on
biofilms, where bacterial metabolism and respiration is likely to be
altered, is poorly understood. Biofilm formation by E. coli is
enhanced after exposure to CO-RMs but whether this is also true
for other bacteria is unknown and has implications for developing
these drugs as antimicrobials [21]. The purpose of this study was
to evaluate the effects of CORM-2, a ruthenium-containing CO-
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formation and surface colonization. Our study demonstrates that
CORM-2 attenuates P. aeruginosa formation at concentrations that
are not toxic for mammalian cells, and that the CORM-2
bactericidal efficiency varies with the P. aeruginosa genetic
background and growth conditions.
Results
CORM-2 kills P. aeruginosa PAO1 during planktonic
growth and biofilm formation
Recent studies have shown that CORM-2, CORM-3 and, to a
lesser extent, CORM-371 have previously been shown to kill
planktonic P. aeruginosa [18,22]. All these CO-RMs contain a
transition metal, either ruthenium (CORM-2 and CORM-3) or
manganese (CORM-371). Our data confirm that CORM-2, but
not its inactive counterpart iCORM, kills planktonic PAO1 in M9
medium supplemented with glucose. The effect was dose-
dependent with a minimal inhibitory concentration of 10 mM
(Figure 1). The vehicle alone (DMSO) did not affect growth of
PAO1 (data not shown). Colony counts of viable bacteria
determined that this killing was rapid with a three-log drop in
recovered bacteria at 20 min and no viable bacteria recovered
after 30 min (data not shown).
We next assessed whether CORM-2 can impact surface
associated P. aeruginosa. Crystal violet (CV) staining of PAO1
biofilms formed in plastic wells demonstrated that a 6 h exposure
to CORM-2 decreased CV biofilm staining with exposure to
concentrations $25 mM of CORM-2 showing a statistically
significant effect (ANOVA p,0.001) (Figure 2A). Post-test
Dunnett’s analysis demonstrated that CV staining levels for all
samples treated with $25 mM CORM-2 were different from the
control but not different from each other. The effect of CORM-2
on biofilm formation compared with vehicle was observed as early
as 60 min after treatment and was statistically significant at 4 h
(p,0.007, paired t-test) (Figure 2B). We next performed colony
counts from sonicated biofilms +/2 100 mM iCORM or 100 mM
CORM-2 to determine if bacterial cell death contributed to
changes in CV of the biofilm. The data demonstrate that there is a
statistically significant two-log drop in the number of viable
bacteria recovered from the CORM-2 treated biofilm when
compared with the initial viable cell counts and 100 mM iCORM
(Figure 2C) (ANOVA,0.001, Dunnett’s post-test analysis). Cell
death is observed as early as 30 min after drug treatment and
persists up to 6 h.
Figure 1. CORM-2 kills planktonic P. aeruginosa. The control molecule iCORM has no effect on PAO1 growth in liquid M9 medium with glucose
(left panel), while CORM-2 doses .5 mM prevent growth of PAO1 (right panel).
doi:10.1371/journal.pone.0035499.g001
Figure 2. CORM-2 attenuates P. aeruginosa biofilm formation. A)
Crystal violet (CV) biomass staining decreases after CORM-2 exposure in
a dose-dependent manner. Each condition was done in triplicate. B) CV
staining of PAO1 biofilms treated with 100 mM CORM-2 demonstrates
decreased staining of the biofilm after 2–6 hours of CORM-2 exposure
compared with DMSO vehicle where the biofilm increases overtime. C)
Colony counts of PAO1 released from the iCORM (100 mM) and CORM-2
(100 mM) treated biofilms demonstrate that there is a sustainable 2-log
drop in bacterial viability.
doi:10.1371/journal.pone.0035499.g002
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We next examined the dynamics of biofilm formation after
addition of CORM-2, iCORM or tobramycin, a known antibiotic
used for P. aeruginosa therapy. PAO1-YFP bacteria were incubated
in glass bottom dishes for 16 h, then gently washed. Fresh medium
with iCORM, DMSO, CORM-2 (50 mM) or tobramycin
(100 mg/ml) was added to surface attached bacteria. Fluorescence
microscopy was used to image the biofilm at a single location over
time. We observed that PAO1 biofilms do not continue to mature
in the presence of CORM-2 compared with biofilms formed in
absence of the drug (compare Figure 3A–D and 3I–L). CORM-2
is as effective as tobramycin (100 mg/ml) in preventing bacterial
growth, thus maturation of PAO1 biofilms (compare Figure 3 I–L
to M–P; see also Figure S1).
No effect on biofilm maturation was observed in the presence of
the iCORM vehicle control (Figure 3 E–H) or DMSO (data not
shown). These data suggest that the release of CO mediated by
CORM-2 prevents further biofilm development, similar to the
growth inhibition observed during planktonic growth. This
observation was confirmed by quantification of bacterial fluores-
cence (Figure S1).
CORM-2 attenuates PAO1 microcolony formation on
human bronchial epithelial cells
We observed that CORM-2 prevents the development of mature
biofilms on plastic and glass. We next decided to examine the effect
of CORM-2 on bacterial colonization of human bronchial epithelial
cells. PAO1-GFP bacteria attached to 16HBE14o- cells were treated
with 50 mM of CORM-2 or DMSOandmicrocolonyformationwas
followed for 6 h with time-lapse microscopy. The addition of 50 mM
CORM-2 inhibited bacterial growth resulting in reduced microcol-
onyformation andlessdamage tothe epithelialcellswhencompared
with DMSO addition (Figure 4 A–H and Movies S1 and S2) or
iCORM (data not shown). Epithelial cell integrity was continuously
assessed by differential interference contrast.
Previous work has shown that CO-RM molecules are not toxic to
mammalian cells [16,23] or when used intravenously in animal
models [7]. We tested whether CORM-2 has a cytotoxic effect on
airway epithelial cells. 16HBE14o- cells were treated with 50 mM,
100 mM and 200 mM of CORM-2 for 6 h or 12 h. Control cells
were treated with vehicle alone (DMSO). CORM-2 was not
associated with any cell toxicity at the doses tested either after 6 h or
12 h exposure (Figure 5 A, B). These data reveal that at bactericidal
concentrations (50 mM– 200 mM) CORM-2 is effective in disrupt-
ing P. aeruginosa surface colonization of biotic surfaces at doses that
are not toxic for human bronchial epithelial cells.
CORM-2- and tobramycin-mediated antimicrobial
activities are additive
Given the difficulty in treating bacterial biofilms, we next sought
to determine if CORM-2 would work as an adjuvant therapeutic
agent with currently available antimicrobials. Tobramycin is an
aminoglycoside antibiotic commonly given by nebulizer to patients
with chronic pulmonary P. aeruginosa infection. One hundred mM
CORM-2 is as effective as 1 mg/mL tobramycin at decreasing
biofilm biomass as measured by CV staining (Figure 6A). The
addition of CORM-2 (100 mM) and tobramycin (1 mg/ml) in
combination for 6 h resulted in decreased CV staining of PAO1
biofilms compared with either no drug or either drug alone with
no recovery of viable bacteria (Figure 6A and data not
shown)(p,0.05 ANOVA, Dunnett’s post-test analysis). To deter-
mine whether there was a difference in the recovery of viable
Figure 3. CORM-2 attenuates PAO1 biofilm formation. YFP-P. aeruginosa were grown for 16 hours in a glass bottom dish and then visualized
at selected locations for 12 additional hours using VivaView. A–D: control (CTR=no addition) biofilm formation; E-H: biofilm formation in presence of
iCORM (50 mM); I–L: biofilm formation in presence of CORM2. The CORM-2 (50 mM) treated biofilm remains unchanged compared with the control
biofilms that continue to mature; M–P: biofilm formation in presence of tobramycin. T indicates time; h indicates hours. Scale bars=50 mm.
doi:10.1371/journal.pone.0035499.g003
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lowered the dose of tobramycin to 100 mg/ml. Exposure to
100 mg/ml tobramycin resulted in a one-log drop in bacterial
viability by 60 min, while exposure to CORM-2 led to a two-log
drop at 60 min (Figure 6B). Exposure to both drugs resulted in an
additive effect with a four-log drop in recovered viable bacteria at
60 min (Figure 6B), as assessed by colony forming units assay.
Bacterial recoveries from all treatments except the 30-minute
tobramycin group were significantly different than the number of
bacteria recovered at t0 (ANOVA,0.001, Dunnett’s post-test
analysis).
Antioxidants protect PAO1 biofilms from CORM-2
inhibition
Previous work on planktonic P. aeruginosa demonstrated that
multiple reducing agents (NAC, L-cysteine, and reduced glutathi-
one) prevent P. aeruginosa killing by CO-RMs [18]. Our initial
Figure 4. CORM-2 attenuates P. aeruginosa colonization of respiratory epithelium. Time –lapse microscopy of bronchial epithelial cells co-
cultured with PAO1 (1:3 ratio) show that the addition of 50 mM of CORM-2 reduced microcolony formation. The time (hours) when the images were
acquired is indicated at the bottom of each panel. Movies are available as supplementary online data (Movies S1 and S2). Scale bars=50 mm.
doi:10.1371/journal.pone.0035499.g004
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cysteine confirmed this protection (data not shown). We next
added NAC or L-cysteine in combination with CORM-2 during
biofilm formation in M9 medium to determine whether the treated
biofilms were protected against CORM-2 induced cell death.
Indeed, CV staining of PAO1 biofilms formed in 96-well plates
exposed to either NAC or L-cysteine in the presence of CORM-2
was similar to untreated biofilm formation (Figure 6A). CORM-2
treatment alone showed a significant decrease in CV staining
compared with controls (no drug or DMSO) (Figure 7A) (p,0.01
ANOVA, Dunnett’s post-test analysis).
Published reports have suggested multiple mechanisms of the
bactericidal action of CO-RMs including ROS-mediated activity
for CORM-2 [18,20,21]. ROS production by PAO1 biofilms
increased after CORM-2 exposure .10 mM as assessed by DCF
fluorescence intensity compared with untreated biofilms
(Figure 7B, ANOVA p,0.001, Dunnett’s post test analysis).
Interestingly, while the addition of NAC to PAO1 biofilms
prevented ROS production, the addition of L-cysteine only
reduced ROS production to levels seen when 25 mM CORM-2
alone is added (Figure 7B). At this concentration, CORM-2 was
sufficient to reduce CV staining (Figure 2A). L-cysteine with
100 mM CORM-2 resulted in no statistical significant decrease in
biofilm formation compared with control samples despite similar
levels of ROS production (Figure 7A) (N.S. by ANOVA).
Therefore, our data support the previous observations that ROS
production is not the major mechanism by which CORM-2
disrupts P. aeruginosa growth in M9 medium with glucose and an
alternative mechanism such as binding of CO to P. aeruginosa
respiratory chain is more likely [22].
Rich medium protects against CORM-2-dependent PAO1
death
We next examined biofilm formation in rich medium, where an
increase in biofilm formation has been observed for E. coli after
CORM-2 addition [21]. In contrast to E. coli, PAO1 biofilm
formation in LB does not change significantly after addition of
CORM-2 (Figure 8A). Planktonic PAO1 grown in shaking LB
were also protected from CORM-2-dependent cell death
(Figure 8B). ROS production by PAO1 biofilms grown in LB
was slightly increased after exposure to 100 mM CORM-2 but not
to the same extent as biofilms grown in minimal media (data not
shown). The nutritional conditions and composition of the growth
medium are therefore critically important in determining the
activity of CORM-2 during both liquid and surface associated
growth and this likely has implications [20] for in vivo efficacy.
Figure 5. CORM-2 does not affect airway epithelial cell
viability. The MTT viability assay shows that 50–200 mM of CORM2 is
not toxic to airway epithelial cells after 6 hours (A) or 12 hours (B)
treatment. As a control for cell death, 16HBE14o- cells were treated with
saponin for 10 minutes before proceeding with the MTT staining.
CORM-2 viability is expressed as percentage of non-treated control cells
(DMSO).
doi:10.1371/journal.pone.0035499.g005
Figure 6. CORM-2 and tobramycin have additive effects on PAO1 biofilm formation. A) CORM-2 (100 mM) is as effective as tobramycin
(1 mg/ml) in decreasing the biomass of the bacterial biofilm after 6 hours treatment, as measured by CV staining and the combination is better than
either alone. B) The combination of CORM-2 (100 mM) and tobramycin (Tobr.) results in increased PAO1 killing within the biofilm than either drug
alone.
doi:10.1371/journal.pone.0035499.g006
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planktonic growth of clinical isolates and PA14
CORM-2 prevents PAO1 planktonic growth and biofilm
maturation. Given the genetic and phenotypic diversity of P.
aeruginosa [24] we next tested the effect of CORM-2 on liquid
growth and the biofilm formation of a number of previously
characterized clinical isolates from respiratory specimens of non-
CF patients [25]. Two of twelve respiratory isolates grew poorly in
liquid M9 minimal medium (isolates #5 and #8) (Figure 9A, left
panel). Of the remaining ten, growth of all strains was inhibited by
the presence of 100 mM CORM-2 (Figure 9, right panel). Ten of
the twelve (83%) strains grown overnight in plastic wells displayed
statistically significant reduced CV staining of the biofilm after 6 h
incubation with 100 mM CORM-2 compared with no treatment
(Figure 9B) (p,0.05, paired t-tests). Three isolates (#3, #4, #10)
formed poor biofilms both in the absence of CORM-2 and when
CORM-2 was added. For these three isolates, the CV staining of
the CORM-2 treated biofilms was similar to the un-inoculated
blank. Two strains unaffected by CORM-2 (#1, #8) formed
robust biofilms compared with PAO1 during standing growth in
M9 with glucose (Figure 9B). These data suggest that while the
majority of respiratory isolates are susceptible to CORM-2
treatment, isolates with robust biofilm formation are less likely to
be affected by CORM-2 treatment. Interestingly, isolate #8 had
poor planktonic growth but robust biofilm formation in M9 with
glucose. These data highlight the role of biofilm formation in the
process of P. aeruginosa strain adaptation to unfavorable metabolic
conditions.
The above strains were from patients without CF and more
likely represent environmental strains and not strains from patients
with chronic infection. Chronic pulmonary P. aeruginosa infection
often results in the selection of alginate producing mucoid strains
[26]. We next examined whether CORM-2 alters the biofilm
formation of isolates recovered from CF patients. We included
both mucoid and non-mucoid clinical isolates from CF patients
along with PDO351(mucA:aac+;alg+), a mucoid strain that is
otherwise isogenic to PAO1 [27] (Figure 9C). Similar to the results
for the non-CF P. aeruginosa isolates we found that CORM-2
reduced biofilm formation in some strains but not all (Figure 9C)
(p,0.012, paired t-test). The efficacy of CORM-2 did not
correlate with the mucoid status of the isolate; for example,
CORM-2 had the same effects on mucoid PDO351 compared
with non-mucoid wild type PAO1 while the biofilm formation of
other mucoid clinical strains were unaffected by the addition of
CORM-2 (Figure 9C). Given that biofilms may form under
anaerobic conditions during chronic pulmonary infection, we
assayed anaerobic planktonic growth in M9 glucose or LB
medium using 40 mM potassium nitrate as an electron acceptor.
Addition of 100 mM CORM-2 inhibited growth of PAO1 in M9
medium but not LB (as observed for aerobic conditions),
demonstrating CORM-2 activity at different oxygen tensions
(Figure S2).
Given the heterogeneity of the effects of CORM-2 on clinical
isolates we next tested the effect of CORM-2 on another
commonly used laboratory strain, PA14 (Figure 10). Similarly to
clinical isolates #5 and #8, PA14 displayed poor planktonic
growth in M9 glucose medium when compared with PAO1 (data
Figure 7. Anti-oxidants protect P. aeruginosa biofilms from CORM-2 inhibition. A) The addition of NAC (1 mM) or L-cysteine (100 mM) to
CORM-2 (100 mM) treated P. aeruginosa biofilms (6 hours) restores CV staining to levels comparable to untreated biofilms. B) Treatment with CORM-2
(25 mM and 100 mM) induces bacterial ROS formation; NAC (1 mM) prevents ROS production while the addition of L-cysteine (100 mM) did alter only
partially ROS levels.
doi:10.1371/journal.pone.0035499.g007
Figure 8. Rich medium protect P. aeruginosa biofilms against
CORM-2. A) Biofilm formation by P. aeruginosa treated with CORM-2
(100 mM) for 6 hours is similar to untreated controls when grown in LB.
B) The addition of CORM-2 (100 mM) to P. aeruginosa growing in liquid
LB medium does not result in cell death.
doi:10.1371/journal.pone.0035499.g008
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prevent planktonic PA14 growth 200 mM CORM-2 was required;
iCORM did not have any effect on PA14 growth at any
concentration (Figure 10A). Interestingly, while planktonic PA14
growth was poor in M9, PA14 formed strong biofilms after
overnight growth in M9 similarly to what observed for PAO1
(Figure 10B). Thus, PA14 displays adaptation to unfavorable
metabolic conditions as also observed for clinical isolates #5 and
#8. PA14 biofilms were insensitive to low doses of CORM-2 (10–
200 mM) (as also observed for clinical isolated #8), and required
much higher doses of CORM-2 (400–600 mM) to inhibit biofilm
formation compared with PAO1 (Figure 10C). These data suggest
that intrinsic differences in P. aeruginosa strains affect their
susceptibility to CORM-2. Since we observed different growth
rates between PAO1 and PA14 stains in minimal M9 medium
supplemented with glucose, we hypothesized that the susceptibility
to CORM-2 is related to the strain-related capability of using
different carbon sources for energy. Our finding that CORM-2
becomes ineffective when either PAO1 or PA14 is grown in rich
LB media (Figure 8 and data not shown) also supports this
hypothesis.
Discussion
In patients with CF, there is a chronic hyper-inflammatory state
within the infected lung that fails to eradicate colonization with
pathogens such as S. aureus and P. aeruginosa leading to clinical
Figure 9. The effect of CORM-2 on growth and biofilm formation of clinical, respiratory P. aeruginosa isolates. A) The addition of
100 mM CORM-2 to M9 liquid medium with glucose (left) prevents the growth of all clinical isolates compared with addition of DMSO alone (right). B)
6 hours exposure to 100 mM CORM-2 reduces the CV staining of 10/12 biofilms formed by respiratory isolates after overnight growth in plastic wells.
C) 100 mM CORM-2 reduces the CV staining of 3 out of 4 biofilms formed by respiratory isolates from CF patients independently of the mucoid or
non-mucoid after overnight growth in plastic wells. A similar effect was observed in mucoid-PAO1 laboratory strain PDO351 (mucA:aac+;alg+).
doi:10.1371/journal.pone.0035499.g009
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initiated with surface attachment followed by microcolony forma-
tion, the precursors to the mature, antibiotic-resistant biofilm [4,5].
Since mature biofilms are difficult to eradicate, an alternative
approach to therapy is to generate novel antimicrobial agents to
prevent these early stages of biofilm formation enhancing the
efficacy of the immune response. CO is an appealing therapeutic
agent because it has the potential to reduce both host pulmonary
inflammation and bacterial viability [15]. CO-RMs were developed
to improve and maximize the effects of CO delivery to tissues and
CORM-2, used in this study, can efficiently release controlled
amount of CO with the same cytoprotective activities that are
described by exogenous administration of CO gas without any
cytotoxic effect on mammalian cells [16].
We demonstrate that, in addition to killing planktonic P. aeruginosa,
CORM-2 also prevents microcolony formation on human bronchial
epithelial cells while maintaining the integrity of the epithelium
(Figure 4). Importantly, CORM-2 concentrations required for P.
aeruginosa killing were not toxic to human airway epithelial cells even
after a 12 hours exposure (Figure 5). We cannot exclude that
CORM-2 prevented epithelial cells disruption not only by impairing
bactericidal growth, but also by enhancing the antimicrobial activity
of mammalian cells. This is an area of active investigation.
CORM-2 also attenuates P. aeruginosa biofilm formation on
abiotic surfaces confirming the antimicrobial effect beyond that
previously shown for planktonic bacteria [17,18] (Figure 2).
Together, these data suggest CORM-2 can inhibit biofilm
formation regardless of the surface used for bacterial attachment.
Despite the genetic and phenotypic diversity of P. aeruginosa, the
majority of clinical isolates from non-CF patients tested had
decreased biofilm formation after exposure to CORM-2 (Figure 7).
Importantly, pulmonary infections in CF patients are usually
initiated by environmental P. aeruginosa strains that often cause
other types of human infection. The two clinical isolates resistant
to CORM-2 formed robust biofilms rapidly when compared with
the other isolates, suggesting that the earlier CORM-2 is applied
the more effective it is likely to be. CORM-2 also attenuated the
biofilm formation of a subset of isolates from CF patients,
including both non-mucoid and mucoid strains. While mucoid and
non-mucoid strains have multiple phenotypic and genetic
differences, mucoidy did not predict failure of CORM-2 treatment
[28]. Interestingly, the commonly used laboratory strain PA14
showed increased resistance to CORM-2 exposure. We hypoth-
esize this is due to its slow growth rate in the presence of glucose
and its ability to adapt to unfavorable metabolic conditions.
Additional studies are required to determine whether metabolic
differences between PA14 and PAO1 are responsible for their
different susceptibility to CORM-2 treatment.
The combination of CORM-2 with tobramycin, an antibiotic
currently used in therapy for P. aeruginosa pulmonary infection in CF
patients, was more effective at killing bacteria and reducing biomass
than either drug alone (Figure 6). To our knowledge this is the first
example of an added benefit when combining CORM-2 with
another antimicrobial agent suggesting CORM-2may have a roleas
an adjuncttherapy with currently available antimicrobials. This may
be particularly helpful during chronic infections where subpopula-
tions of antibiotic resistant bacteria persist after treatment.
Exposure of E. coli to CORM-2 results in increased ROS
production, DNA damage and intracellular iron levels of iron [20],
suggesting that ROS generation is the primary mechanism of cell
death [20]. ROS production does not appear to be the mechanism
of CORM-2 dependent PAO1 cell death in liquid growth [22].
Interestingly, while ROS production is increased from P. aeruginosa
biofilms after CORM-2 exposure, the addition of L-cysteine only
Figure 10. High doses of CORM-2 are required to reduce growth and biofilm formation of PA14. A) CORM-2 doses .100 mM (right panel)
but not iCORM (left panel) prevents PA14 growth in liquid M9 medium with glucose. B) As measured by CV staining, PA14 biofilms are resistant to the
low doses of CORM2 treatment (10–200 mM) that reduce PAO1 biofilm formation. C) Higher doses of CORM-2 (400 mM and 600 mM) decreases CV
staining of both PA14 and PAO1 biofilm formation. Each condition was tested in triplicate.
doi:10.1371/journal.pone.0035499.g010
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aeruginosa biofilm formation from the effects of CORM-2 (Figure 7).
This suggests that ROS do not cause cell death in CORM-2
treated biofilms. The mechanism of protection provided by
reducing agents to P. aeruginosa observed by us and others remains
unknown [20]. Microarray analysis of E. coli exposed to CO-RMs
also demonstrate a global effect with transcriptional changes in a
wide variety of metabolic pathways and transcriptional regulators,
including those involved in carbohydrate production, energy
metabolism, and stress response [19,21]. Whether any of the
above transcriptional changes occur in P. aeruginosa and contribute
to CORM-dependent cell death is unclear.
Exposure to CO-RMs has been shown to result in CO binding
to components of the respiratory chain in both E. coli and P.
aeruginosa [18,19]. The P. aeruginosa respiratory chain is complex
and involves a large number of respiratory oxidases [29]. At least
two cytochrome oxidases interact with CORM-3 as assayed via
dual wave spectrophotometry [18]. Exposure of planktonic
cultures to CORM-3 results in a temporal decrease in oxygen
consumption consistent with the hypothesis that interference of
CO with the respiratory chain kills P. aeruginosa [18]. CORM-2
inhibits E.coli, Camplyobacter jejuni and P. aeruginosa PAO1 also under
anaerobic conditions [19,30], suggesting that oxygen is not
required as the terminal electron acceptor for CORM-2 activity.
In LB-rich medium P. aeruginosa planktonic growth and biofilm
formation are unaffected by CORM-2. This is in contrast to E. coli
where CO-RMs increase both oxidative stress and biofilm
formation [21]. The reason CORM-2 is not effective during
growth in rich medium is unknown. One hypothesis currently
being tested is that the active energy pathways used by P. aeruginosa
determine its susceptibility to CORM-2 and are dependent on the
nutritional environment and bacterial growth rate. Given the
genetic and phenotypic variability of P. aeruginosa, these observa-
tions are of particular importance since intrinsic differences in
metabolism amongst P. aeruginosa strains may limit the effectiveness
of therapies that target energy production.
In conclusion, this report demonstrates that, in addition to
infections that likely involve planktonic bacteria such as bacteremia,
CO-RMs are a potential therapeutic option for P. aeruginosa surface-
associated infections with a biofilm component such as pulmonary
and perhaps burn infections [18]. Since CORM-2 demonstrated
activity against mucoid strains and under anaerobic conditions it
hasthepotentialtohaveaneffectonchronicP.aeruginosapulmonary
infections as observed in patients with long-standing lung disease
such as CF. However, as several clinical isolates and PA14 were
resistant to CORM-2 dependent killing, this compound will not
work for all infections and the emergence of resistant strains is
possible. We hypothesize that the nutrients available and the energy
pathways used by P. aeruginosa in the host during infection will be
critical in determine the potential for CO-RMs as in vivo
therapeutics. This is an important area for additional studies.
Importantly, a single dose of CORM-2 achieved significant
bacterial killing for most isolates. If CORM-2 were dosed more
frequently, we hypothesize it will result in additional bacterial death
within the biofilm. Current efforts are underway to improve CORM-
2-dependent biofilm disruption andb e t t e ru n d e r s t a n dt h em e c h a n i s m s
of both CORM-2 action within P. aeruginosa and CORM-2 resistance
in non-susceptible strains or in different metabolic conditions.
Methods
Drugs
CORM-2, which contains a ruthenium metal surrounded by six
carbonyl (CO) groups, was dissolved in DMSO (stock solution
10 mM) (Sigma-Aldrich, St Louis MO). As a negative control for
CORM-2, an inactive compound, here referred to as iCORM,
was used (stock solution 10 mM). This compound [Ru(DM-
SO)4Cl2) consists of a ruthenium metal where the CO groups have
been replaced by DMSO [11]. Both drugs were diluted to final
concentrations of 10–600 mM, depending on the experiment.
Stocks were prepared fresh for each experiment. Tobramycin
(stock solution 100 mg/ml) (MP Biomedicals, Solon OH) was used
at final concentrations ranging from 100 mg to 1 mg/ml,
depending on the experiment. N-acetyl cysteine (NAC) was added
at a final concentration of 1 mM and L-cysteine was used at
100 mM [18].
Strains and Growth Conditions
PAO1 is the reference laboratory strain used in all experiments
except where described. In some experiments, the mucoid
PDO351(mucA:aac+;alg+) strain, derived from PAO1, was used
[27]. The effect of CORM-2 on clinical isolates was determined
using previously characterized P. aeruginosa respiratory isolates
from patients without CF [25] and isolates from patients with CF.
M9 salts growth medium was supplemented with 0.4% glucose.
Vogel Bonner Medium (VBM) agar plates selective for P. aeruginosa
were made as described [25]. The expression of the yellow
fluorescent protein (YFP) from the plasmid pMQ72 in PAO1 was
induced by supplementing the media with arabinose (0.02%) [31].
PAO1 expressing green fluorescent protein (GFP) from the high
copy plasmid pUCPSK was grown overnight in the presence of
carbenicillin (200 mg/ml). The PAO1-GFP bacteria were washed
and resuspended in M9 medium without carbenicillin prior to
incubation with respiratory epithelial cells. For growth experi-
ments, overnight cultures of PAO1 were diluted into fresh medium
to an optical density (OD) at 600 nm of 0.05, the CORM-2,
iCORM, or DMSO added, and the OD followed over time. At
specified intervals, aliquots were removed from the cultures,
diluted to VBM agar plates, and incubated overnight at 37uCt o
determine the number of viable bacteria. In some growth
experiments, another laboratory strain, PA14, was used. PA14
was also diluted to an OD (600 nm) of 0.05 from overnight
cultures grown aerobically at 37uC in Luria-Bertani broth (EMD)
or M9 salts growth medium was supplemented with 0.4% glucose.
The CORM-2, iCORM or DMSO treatment was added and the
OD at 600 nm was followed over time using a Biotek Synergy 4
spectrophotometer.
The effect of CORM-2 on PAO1 growth in anaerobic
conditions was also tested. Luria-Bertani broth (EMD) and M9
medium with 0.4% glucose as the carbon source both supple-
mented with 40 mM KNO3 were autoclaved and moved into a
Coy anaerobic chamber (80%/15%/5% N2/CO2/H2 atmo-
sphere) 16 hours before inoculation. Pre-cultures were grown
aerobically overnight and moved into the anaerobic chamber for
use as inocula. Anaerobic media were dispensed 5 mL per
186150 mm anaerobic Balch tube (Bellco) and inoculated to a
final OD (600 nm) of 0.05. Cultures were stoppered and crimp-
sealed in the chamber, then incubated at 37uC with shaking at
250 rpm. OD at 600 nm was followed using a Thermo Spectronic
20D+ spectrophotometer.
Ethics Statement
Clinical P. aeruginosa isolates were taken from de-identified
frozen stocks conserved at 280uC as part of a previous study
approved by the Human Investigations Committee at Yale. These
bacteria were recovered from pediatric and adult patients
hospitalized at Yale-New Haven Hospital and identified by the
clinical microbiology laboratory, as described in previously in
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Static biofilm formation and analysis
PAO1 static biofilms were formed in either 24-well plastic dishes
(Corning, Lowell MA) or 96-well plastic dishes (Grenier bio-one,
Germany). PA14 static biofilms were formed in 96-well plastic
dishes (Grenier bio-one, Germany); the bacteria were inoculated
from an overnight shaking culture to an OD (600 nm) of 0.05 and
then incubated as a static (non-shaking) culture from 18 to
24 hours at 37uC [32]. Under these conditions, a biofilm forms
around the edge of the miniscus against the wall of the well.
CORM-2, iCORM, DMSO, and/or tobramycin were added
directly without removing planktonic cells after biofilm formation.
In a different set of experiments, the planktonic cells were removed
and the remaining biofilm was gently washed before adding fresh
medium with CORM-2 or controls (DMSO or iCORM). At
selected times, the biofilm was washed in water, stained with
0.05% crystal violet (CV) and absorption at 595 nm was recorded
[32]. For a single experiment, the drug additions were tested in
triplicate and all experiments were repeated at least three times.
To recover viable bacteria from mature biofilms, the planktonic
culture was removed after overnight growth, the biofilms were
gently washed, and fresh medium with drug was added for 30 min
to 6 hours. Following this incubation, the biofilms were washed 4
times with fresh medium, then sonicated to release bacteria [32].
The medium containing the released bacteria was serially diluted
and plated on VBM agar. In all experiments, 3 wells on each plate
were initially washed and sonicated to determine the viable cell
counts at time point t0.
Analysis of biofilm formation in real time
For real-time imaging of the effects of CORM-2 on biofilm
formation, PAO1-YFP was grown overnight in glass bottom poly-
lysine coated dishes (MatTek, Ashland MA) [33] and then placed
in a VivaView incubator fluorescent microscopy system (Olympus,
Center Valley PA), and equilibrated at 37uC. CORM-2 (50 mM),
iCORM (50 mM), tobramycin (100 mg/ml) or DMSO was added
and images were collected every 15 minutes for 8 hours. The
images from three fields for each sample were collected and
analyzed with VivaView software.
Microcolony formation on respiratory epithelial cells
The static bacteria/bronchial epithelial cell co-culture system
was established as described [33]. 16HBE14o- bronchial epithelial
cells (a kind gift of Dr. Dieter Gruenert) were maintained in
Minimum Essential Medium supplemented with 10% fetal bovine
serum, L-glutamine and penicillin/streptomycin. For time-lapse
microscopy experiments, 1610
6 cells were plated in collagen/
fibronectin coated glass bottom 3 cm dishes (MatTek, Ashland
MA) and cultured for 5–7 days, allowing for tight junction
formation. Subsequently the epithelial cells were inoculated with
P. aeruginosa-GFP at a ratio of 1:3 in media without antibiotics.
After 40 minutes in culture, unattached planktonic P. aeruginosa
were removed by rinsing and replaced with fresh M9 medium
supplemented with glucose, L-glutamine and 0.04% L-arginine.
CORM-2 (50 mM), iCORM (50 mM) or DMSO was added and
images were collected by time-lapse microscopy (VivaView,
Olympus) every 10 minutes for 6 hours (objective 206). The
epithelium integrity was assessed by differential interference
contrast and remained intact for 7–8 hours of culture in the
absence of bacteria. The images from three fields for each sample
were collected and analyzed with VivaView software.
Cell Viability Assay
16HBE14o- bronchial epithelial cells were seeded in 96-wells
plate (5610
4 cells/well). After 5 days of culture in Minimum
Essential Medium supplemented with 10% fetal bovine serum, L-
glutamine and penicillin/streptomycin, cells were treated with
different doses of CORM-2 (50 mM, 100 mM and 200 mM) or with
vehicle alone (DMSO) for 6 hours or 12 hours. The cell viability
was then assessed using the MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium Bromide) colorimetric assay, which
measures cellular metabolic activity. As control for cell death,
16HBE14o- cells were treated with saponin for 10 minutes before
proceeding with the MTT staining. The MTT staining and the
colorimetric detection (Cell Biolabs, INC) were performed
following the manufacturer’s instructions. Each condition was
performed in triplicate.
Measurement of ROS production in bacteria
To determine ROS production, static biofilms were grown in
96-well plastic dishes (Corning, Lowell MA) as described above
[32]. Biofilms were washed gently and CORM-2 (25 mMo r
100 mM) or DMSO in the absence or presence of NAC (1 mM) or
L-cysteine (100 mM) were added to the biofilm for 2 hours at
37uC. Biofilms were then washed in Phosphate Buffered Saline
(PBS) and loaded with 10 mM 5-(and-6)-chloromethyl-29,79-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-
H2DCFDA; Molecular Probes) for 30 min at 37uC. This was
followed by two washes in PBS. In the presence of intracellular
ROS and esterases, CM-H2DCFDA is oxidized and deacetylated
yielding the fluorescent molecule 29,79-dichlorodihydrofluorescein
diacetate (DCF). Fluorescence intensity was assessed using a
fluorescence plate reader (arbitrary units).
Statistical analysis
Data was compiled in Excel and transferred to Minitab for
statistical analysis. For data derived from biofilm analysis using the
CV method, for analysis of ROS production and for the analysis of
cell viability statistical comparison of paired means was done with
a paired t-test. When required, multiple comparisons of means
were done using a one-way ANOVA. Post-test analysis determin-
ing confidence intervals for individual means was done with
Dunnett’s analysis comparing treated samples to the control.
Supporting Information
Figure S1 CORM-2 attenuates PAO1 biofilm formation.
(A) Mean fluorescence intensity (MFI) of YFP-P. aeruginosa grown
for 16 hours in a glass bottom dish and then visualized at selected
locations for 12 additional hours using VivaView. MFI over time
was normalized to the MFI at time 0 h. CTR=no addition
control; iCORM (50 mM); CORM-2 (50 mM). (B) P values for
each group comparison are shown (t-test).
(PDF)
Figure S2 CORM-2 inhibits anaerobic growth of PAO1
in M9 glucose medium. PAO1 was grown anaerobically in M9
glucose or LB medium in the presence of 40 mM nitrate. Addition
of CORM-2 (100 mM) inhibited planktonic growth of PAO1 in
M9 but not in LB.
(PDF)
Movie S1 CORM-2 attenuates PAO1 microcolony for-
mation on human bronchial epithelial cells. Time–lapse
microscopy of bronchial epithelial cells co-cultured with PAO1
(1:3 ratio) in presence of vehicle control (DMSO).
(MP4)
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mation on human bronchial epithelial cells. Time–lapse
microscopy of bronchial epithelial cells co-cultured with PAO1
(1:3 ratio) in presence of CORM-2 (50 mM). CORM-2 reduced
microcolony formation.
(MP4)
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